- Home
- RXRX vs VCYT Comparison
RXRX vs VCYT Comparison
Compare RXRX & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- VCYT
- Stock Information
- Founded
- RXRX 2013
- VCYT 2006
- Country
- RXRX United States
- VCYT United States
- Employees
- RXRX N/A
- VCYT N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- VCYT Medical Specialities
- Sector
- RXRX Health Care
- VCYT Health Care
- Exchange
- RXRX Nasdaq
- VCYT Nasdaq
- Market Cap
- RXRX 2.0B
- VCYT 2.1B
- IPO Year
- RXRX 2021
- VCYT 2013
- Fundamental
- Price
- RXRX $6.49
- VCYT $25.25
- Analyst Decision
- RXRX Buy
- VCYT Buy
- Analyst Count
- RXRX 5
- VCYT 9
- Target Price
- RXRX $7.00
- VCYT $39.89
- AVG Volume (30 Days)
- RXRX 34.3M
- VCYT 1.2M
- Earning Date
- RXRX 08-07-2025
- VCYT 08-06-2025
- Dividend Yield
- RXRX N/A
- VCYT N/A
- EPS Growth
- RXRX N/A
- VCYT N/A
- EPS
- RXRX N/A
- VCYT 0.41
- Revenue
- RXRX $59,790,000.00
- VCYT $463,393,000.00
- Revenue This Year
- RXRX $23.85
- VCYT $12.55
- Revenue Next Year
- RXRX $43.06
- VCYT $9.79
- P/E Ratio
- RXRX N/A
- VCYT $60.95
- Revenue Growth
- RXRX 29.32
- VCYT 23.42
- 52 Week Low
- RXRX $3.79
- VCYT $19.73
- 52 Week High
- RXRX $12.36
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- RXRX 66.22
- VCYT 46.91
- Support Level
- RXRX $5.13
- VCYT $22.61
- Resistance Level
- RXRX $7.14
- VCYT $27.91
- Average True Range (ATR)
- RXRX 0.49
- VCYT 1.04
- MACD
- RXRX 0.10
- VCYT -0.11
- Stochastic Oscillator
- RXRX 69.30
- VCYT 49.86
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.